BlinkLab

Blinklab Signs Partnership for Clinical Trial with European INTER-PSY, Supporting US and EU Regulatory Approval and Future Market Adoption

Partnership with INTER-PSY to run a prospective clinical trial on early-diagnosis of autism.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”), an innovative digital healthcare company developing smartphone-based AI powered sensory assessments to aid in the diagnosis of neurodevelopmental conditions including autism and ADHD, is pleased to announce a research and clinical partnership with the INTER-PSY (“Agreement”) in the Netherlands (https://interpsy.interpsygroep.nl/).


Highlights

  • Prospective clinical data in young children with autism will optimise BlinkLab’s experimental and AI algorithms.
  • Partnership will accelerate BlinkLab’s path to US and European regulatory approval for autism and clinical adoption.
  • Partnership will support adoption of BlinkLab as a diagnostic tool within the autism diagnostic community in Europe.
  • As part of the larger SCANNER consortium in Europe, this study will also specifically address a need for accelerated autism diagnosis in females.
  • Commencement of FDA 510(k) registration trial on track for later this year.

As part of the Agreement, INTER-PSY will run a prospective study on the ability of the BlinkLab app to aid in diagnosis of autism in children between 2-6 years of age that are referred to INTER-PSY. By analysing the behavioural and physiological responses collected via the app, BlinkLab will aim to identify autism characteristics, potentially offering patients a more rapid, accessible and objective assessment method.

Through this partnership, INTER-PSY will use BlinkLab’s technology to evaluate whether the technology can enhance their diagnostic accuracy and efficiency in the clinic. This partnership between BlinkLab and INTER-PSY demonstrates the potential of an AI mobile health platform to improve and accelerate mental health diagnostics.

INTER-PSY Study and Preparations for FDA 510(k) Regulatory Trial

The INTER-PSY study, which mirrors the design of the upcoming FDA regulatory trial, will be conducted as a single-site, prospective, double-blind, within-subject comparison study (pre- registered). Data gathered from this collaboration will be pivotal in refining the final experimental parameters and optimising machine learning algorithms for BlinkLab’s 510(k) FDA registrational study, specifically targeting diagnostic applications. INTER-PSY is a large autism expertise centre in the Netherlands, offering diagnostics, guidance, and treatment for young children, adolescents, adults, and the elderly with psychological and psychiatric complaints.

Els Blijd-Hogewys, INTER-PSY, commented:

“INTER-PSY is committed to supporting young children with autism in an efficient and effective manner. Our goal is to implement a ‘no waiting time policy’ between diagnosis and the start of therapy, working collaboratively with clients to help them take control of their lives and minimise the impact of autism on daily tasks. Integrating objective measurements can help in the diagnostic process, offering significant benefits to children, their families, and our providers. We believe that BlinkLab's innovative AI platform presents a promising solution for sensory assessments in autism, delivering a short, pleasant and child-friendly test experience. Research will be conducted at INTER-PSY's Expertise Team for Young Children (<6 years). In the future, the instrument could also be valuable for adults with autism.

Unfortunately, the waiting lists for autism assessment for adults in the Netherlands are often as long as 2 to 3 years. Such an instrument may help accelerate this process.”

Mr. Brian Leedman, Chairman BlinkLab, commented:

“Australia has comparable wait times for diagnosis of autism as experienced in Europe and the US. Our BlinkLab technology has the potential to significantly reduce wait times through early diagnosis resulting in treatment at a formative age where early intervention can lead to better outcomes for children and their caregivers.”

Dr. Henk-Jan Boele, CEO BlinkLab, commented:

“Our collaboration with INTER-PSY is one of the final steps in the prospective validation of BlinkLab’s platform before we commence our FDA registration trial later this year. I’m deeply appreciative of INTER-PSY’s partnership on this critical journey. As part of the large SCANNER consortium in Europe, this study with INTER-PSY will also specifically address autism diagnosis in females. Our BlinkLab team is in the final phase of fine-tuning our AI models and algorithms to ensure they meet the highest standards of accuracy, safety, and efficiency. We remain fully committed to executing our strategy and delivering long-term value to all our stakeholders.”

About the SCANNER Consortium

The SCANNER Consortium in Europe, of which BlinkLab is a member, was recently awarded with a 5.3M Euros grant from the Dutch Research Council. The mission of this consortium is to investigate sex differences in autism at a gene, brain and behaviour level. Autism is diagnosed four times more often in men than in women (Autism Spectrum Disorder, APA, 2013). However, little is known about the biological mechanisms behind this disparity, or to what extent this overrepresentation in males is due to bias in the medical research that is also present during the diagnostic process.

Historically, female participants have often been excluded from medical studies, resulting in data being collected primarily from men and generalised to women (Merone et al., 2022).

Similar biases are present in basic research, where men are overrepresented due to the lack of the estrus cycle, resulting in a large gap in our basic biological and clinical knowledge.

This translates into real-life disadvantages for women with neurodivergent conditions, as doctors often ignore the behaviours presented by women. This means that women are less likely to be referred for diagnostic tests and receive timely support, with long-lasting negative consequences for their quality of life. It is therefore crucial to involve women at all levels of research.

Dr. Aleksandra Badura, Lead Investigator SCANNER, commented:

“Within SCANNER we aim to understand how genetic, neurophysiological and behavioural sex differences contribute to autistic traits, and distinguish these biological factors from possible diagnostic bias. Our long-term goal is to improve the diagnostic process for autism and other neurodivergent disorders by taking sex differences into account at all levels of research and diagnosis.”

In addition to INTER-PSY, BlinkLab collaborates in the SCANNER Consortium with Vrije Universiteit Amsterdam; Karakter - Academic Center for Child and Adolescent Psychiatry; Radboud University; Medical Center, Radboud University; Universiteit Utrecht; HAS green academy; Erasmus MC; Netherlands Institute for Neuroscience; Nivel – Netherlands Institute for Health Services Research; University of Twente; Philips Medical Systems Nederland B.V. (Philips MR); Nederlandse Vereniging voor Autisme; Arivis, Noldus Information Technology; Sophia Foundation; WOMEN Inc.; Female Autism Network of the Netherlands; Netherlands Autism Register; Generation R; National association of general practice mental health professionals; Alliantie Gender & Gezondheid; National network autism in young children; National network of child and adolescent psychiatry; Special Olympics Netherlands.


Click here for the full ASX Release

This article includes content from Blinklab Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

BB1:AU
The Conversation (0)
Robotic arm assembling chips with NVIDIA logo and "Tech 5" text overlay.

Tech 5: NVIDIA Results Rattle Investors, Trump Signals More Tech Deals to Come

Artificial intelligence (AI) stocks saw continued pressure this week as concerns about overvaluation weighed on the sector ahead of NVIDIA's (NASDAQ:NVDA) results release for its second fiscal quarter.

The company beat Wall Street projections on revenue, earnings and profits, but shares still fell in extended trading on Tuesday (August 26) after it reported no H20 sales to China, where competition from domestic firms is heating up.

John Murillo, chief business officer at B2BROKER, suggested the pullback could present a short-term buying opportunity for high-quality names with strong fundamentals, but cautioned that it could be the start of a broader correction.

Keep reading...Show less
NVIDIA logo.

NVIDIA Delivers Record Quarter as AI Demand Booms, but China Uncertainty Persists

NVIDIA (NASDAQ:NVDA) delivered another blockbuster quarter, reporting record revenue of US$46.7 billion for its second fiscal period as demand for artificial intelligence (AI) infrastructure continues to surge.

The chipmaking giant said sales rose 56 percent from a year earlier and 6 percent from the prior quarter, marking the ninth straight period of year-on-year revenue growth above 50 percent.

Meanwhile, NVIDIA's net income jumped 59 percent to US$26.42 billion from US$16.6 billion. Its adjusted earnings per share were US$1.05, beating analyst forecasts of US$1.01.

Keep reading...Show less
Digital globe with glowing blue patterns and network connections.

ResetData Creates New Public Sovereign AI Supercomputer in Australia

Australian cloud provider ResetData, part of Centuria Capital Group (ASX:CNI), has unveiled AI-F1, a public sovereign artificial intelligence (AI) supercomputer located in Australia.

AI-F1 offers onshore, high-performance AI computing resources for the government, academic and business sectors.

The multi-megawatt supercomputer allows customers to leverage NVIDIA's (NASDAQ:NVDA) NIM microservices, which are designed to work on machine learning and large language models.

Keep reading...Show less
Futuristic 3D microchip with glowing circuits on a blue background.

NVIDIA's Latest AI Chip Comes at Crucial Moment Before Earnings Report

Reports are circulating that NVIDIA (NASDAQ:NVDA) is quietly preparing a new artificial intelligence (AI) chip for China that would surpass the performance of its current H20 model.

The move comes as the US weighs how much access Chinese companies should have to American technology.

Two people briefed on the matter told Reuters that the chip, tentatively called the B30A, is based on NVIDIA's latest Blackwell architecture and is expected to deliver roughly half the computing power of the company’s flagship dual-die B300 accelerator card. Like the H20, the new chip is rumored to include high-bandwidth memory and NVLink interconnect technology, but would offer more power for Chinese clients.

Keep reading...Show less
Two businesspeople shaking hands over financial graphs and "Tech 5" text.

Tech 5: US Government Strikes Big Tech Deal, Perplexity Plots Expansion

Tech stocks led Wall Street to a second consecutive week of gains as a series of data releases reignited optimism about a September interest rate cut from the US Federal Reserve.

A strong consumer price index report was the catalyst, renewing anticipation that the Fed will lower rates when it meets next month. While Thursday's (August 14) less optimistic producer price index report caused a momentary pause, the tech sector's resilience — or defiance — mitigated losses and kept momentum alive.

Here's a look at the key moments that shaped the tech sector this week.

Keep reading...Show less

Latest Press Releases

Related News

×